The current state-of-the-art for drug-carrying biomedical devices is mostly limited to those that release a single drug. Yet there are many situations in which more than one therapeutic agent is needed. Also, most polyelectrolyte multilayer films intended for drug delivery are loaded with active molecules only during multilayer film preparation. In this paper, we present the integration of capsules as vehicles within polypeptide multilayer films for sustained release of multiple oppositely charged drug molecules using layer-by-layer nanoassembly technology. Calcium carbonate (CaCO 3 ) particles were impregnated with polyelectrolytes, shelled with polyelectrolyte multilayers, and then assembled onto polypeptide multilayer films using glutaraldehyde. Capsule-integrated polypeptide multilayer films were obtained after decomposition of CaCO 3 templates. Two oppositely charged drugs were loaded into capsules within polypeptide multilayer films postpreparation based on electrostatic interactions between the drugs and the polyelectrolytes impregnated within capsules. We determined that the developed innovative capsule-integrated polypeptide multilayer films could be used to load multiple drugs of very different properties (e.g., opposite charges) any time postpreparation (e.g., minutes before surgical implantation inside an operating room), and such capsule-integrated films allowed simultaneous delivery of two oppositely charged drug molecules and a sustained (up to two weeks or longer) and sequential release was achieved.
Introduction
Due to its high degree of control over film properties, flexible choice of assembly components, and ease of processing, layerby-layer (LBL) nanoassembly has been widely used as a versatile technique for fabricating polyelectrolyte multilayer films and microcapsules with precisely controlled structures and compositions. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The films and microcapsules are typically built by alternative adsorption of polymers with complementary functional groups based on electrostatic interactions, 1, 2, [4] [5] [6] [7] [8] [9] [10] hydrogen bonding, 3, 6, 11, 12 hydrophilicity/hydrophobicity, 13, 14 and covalent interactions. 15, 16 Polyelectrolyte microcapsules have shown great potential application in drug delivery and polyelectrolyte films have applications in optics, electronics, and biomedical devices. 3, [17] [18] [19] [20] [21] [22] Recently, increasing interest has been drawn to developing drug-carrying films at the implant/tissue interface to prevent device-associated infections. [23] [24] [25] [26] [27] Millions of medical devices are implanted in patients every year 28, 29 and device-associated infections and related wound healing are significant clinical complications of almost all kinds of prosthetic medical devices. [30] [31] [32] [33] Drug-carrying films on implantable medical devices may play an important role in preventing device-associated infections and promoting wound healing; the current state-ofthe-art for drug-carrying devices is mostly limited to those that release a single drug. Polyelectrolyte multilayer films carrying a single drug have been studied by assembly of charged drugs or drug-conjugated polymers as film components, and by postincorporation of drugs into the films. [34] [35] [36] [37] In addition, amphiphilic polymers, hydrogels, and micelles have been introduced in polyelectrolyte multilayer films for drug delivery control. [38] [39] [40] [41] [42] However, there are many situations in which more than one therapeutic agent is needed. To give an example, drugcarrying implants that deliver multiple therapeutic drugs such as antibiotics and growth factors may not only prevent deviceassociated infections, but also promote wound healing, thereby achieving ideal treatment outcomes. As a result, a number of researchers have directly incorporated two or more drugs into polyelectrolyte multilayers and controlled release has been observed. [43] [44] [45] [46] For instance, Hammond and colleagues have engineered hydrolytically degradable multilayer films to release multiple drugs through control of the interlayer diffusion and/ or the degradation of the multilayers. 43, 45 Functionalized nanoparticles have also recently been integrated within polyelectrolyte multilayer films. 46 However, most of these polyelectrolyte multilayer films have been loaded with drugs only during film preparation. Finding a method to load multiple drugs in the films postpreparation is of great significance because it relieves the concerns over drug storage in the films and opens the opportunity for the surgeons to load the appropriate drugs minutes before surgical implantations.
In this study, we present the development of innovative capsule-integrated polypeptide multilayer films that allow for postpreparation loading and release of multiple therapeutic agents of different properties (e.g., opposite charges). Capsules impregnated with polyelectrolytes, serving as drug binding agents, were integrated as layers in polypeptide multilayer films. Charged drug molecules, both small and large, were tunably (e.g., via incubation time) attracted into capsules that were impregnated with oppositely charged polyelectrolytes. Sustained release of two oppositely charged drug molecules from one single polypeptide multilayer film was obtained.
Materials and Methods

Materials.
Poly-L-lysine hydrobromide (PLL, MW 150-300 kDa), poly-L-(glutamic acid) (PLGA, MW 50 kDa), glycine, fluoresceinisothiocyanate-labeled bovine serum albumin (FITC-BSA), gentamicin sulfate, and glutaraldehyde (GA) were purchased from Sigma (St. Louis, MO). CaCO 3 particles were purchased from PlasmaChem Gmbh (Rudower Chaussee, Berlin, Germany). Disodium ethylenediaminetetraacetic acid (EDTA) was obtained from Fisher (Fair Lawn, NJ). Quartz slides were purchased from Electron Microscopy Sciences (Hatfield, PA), cut into 1 × 2 cm 2 , and cleaned in a piranha solution (4:1 H 2 SO 4 / H 2 O 2 ), followed by rinsing with deionized water. A 0.1 M phosphate buffered saline (PBS, pH 7.4) was prepared and used throughout this study. PLL and PLGA solutions were prepared by dissolving PLL and PLGA, respectively, in PBS. Fluorescein-isothiocyanate labeled PLL (FITC-PLL) and gentamicin (FITC-gentamicin)-and Rhodamine Blabeled PLGA (RhoB-PLGA) and gentamicin (RhoB-gentamicin) were prepared.
Impregnation of Polyelectrolytes in Microparticles and
Subsequent Nanoassembly of Multilayered Shells on Polyelectrolyte-Impregnated Microparticles. Polyelectrolytes (i.e., PLL or PLGA) were impregnated into CaCO 3 particles. Briefly, CaCO 3 colloidal particles (200 mg) were immersed in 1, 2, or 5 mg/mL PLL or PLGA solution and incubated for 30 min in a vacuum chamber (3 Torr). After centrifugation, the supernatant was removed and the particles were dried at 60°C under vacuum (380 Torr) overnight. Polypeptides (i.e., PLL and PLGA) were then alternatively used to form a shell on these particles using LBL nanoassembly to form shelled CaCO 3 particles. Briefly, polyelectrolyte-impregnated CaCO 3 particles (200 mg) were incubated in 1 mg/mL PLL solution for 20 min, washed three times by immersing them in a glycine solution (pH 7.4) for 1 min, followed by centrifugation at 5000 rpm for 0.5 min. The microparticles were then incubated in 1 mg/mL PLGA solution for 20 min and washed three times. The deposition of PLL and PLGA layers was repeated three times followed by an additional assembling of PLL as the outermost layer. As a result, (PLL/PLGA) 3.5 was formed on the CaCO 3 particles. These shelled CaCO 3 particles were then subjected to crosslinking by incubating them in a GA solution at ambient temperature for 2 h, and as a result, the surfaces of CaCO 3 particles were enabled with aldehyde groups due to the use of excessive GA (see Supporting Information). The particles were finally washed three times in deionized water and kept at 4°C for further use; these PLL and PLGA impregnated CaCO 3 particles with aldehyde groups on the surfaces were designated as CaCO 3 PLL and CaCO 3 PLGA , respectively. To form capsules, 0.1 g of CaCO 3 PLL or CaCO 3 PLGA particles was incubated in a 0.1 M EDTA solution for 1 h, followed by centrifugation and removal of supernatants. Such incubation was repeated three times to dissolve the CaCO 3 templates.
To quantify the impregnated PLL or PLGA within CaCO 3 particles, FITC-PLL and RhoB-PLGA were used to prepare CaCO 3 FITC-PLL and CaCO 3 RhoB-PLGA particles, and unlabeled PLL and PLGA were used to form (PLL/PLGA) 3.5 layers on the particles. The CaCO 3 templates were decomposed, and the particles were sonicated for 20 min. FITC-PLL and RhoB-PLGA were quantified by measuring their peak absorbance at 480 and 560 nm, respectively, using UV-vis spectrometry (BioMate 3 UV-vis spectrophotometer, NY). Standard curves were obtained by measuring the absorbance of known concentrations of FITC-PLL and RhoB-PLGA. In addition, the impregnated PLL or PLGA were also quantified by measuring the supernatant polymer concentrations before and after incubation with CaCO 3 particles. No significant differences were observed between the two quantification approaches.
Formation of Capsule-Integrated Polypeptide Multilayer Films.
Polypeptide multilayer films were prepared using a dippingmachine (Riegler and Kirstein Gmbh, Germany). The procedure to form capsule-integrated multilayer films was as follows (see Figure 1 ). (i) Substrate (i.e., quartz slide) was dipped into a PLL solution for 10 min and washed with PBS for 3 min, followed by air drying. Next, the substrate was dipped in a PLGA solution, washed, and dried. The process was repeated to form (PLL/PLGA) 3.5 layers on the substrate ( Figure 1a ). (ii) The substrate was then dipped into a suspension (1 mL) of shelled CaCO 3 PLL particles with aldehyde groups for 60 min at a particle density of 2.0 × 10 8 /ml, which was estimated using hemocytometry and washed with deionized water three times for 3 min (Figure 1b ). (iii) Subsequent deposition of (PLL/PLGA) 10.5 was conducted using LBL nanoassembly, as described in step (i) ( 10.5 were prepared. Note that the assembly of PLL/PLGA multilayers was due to electrostatic interactions between PLL and PLGA, and the integration of Capsule PLL and Capsule PLGA was due to the interactions between the aldehyde groups on the capsule surfaces and the amino groups of PLL (see Supporting Information). The morphology of capsuleintegrated films was examined using scanning electron microscopy (SEM, Hitachi S-4700, Tokyo, Japan) operated under a voltage of 5 kV. Energy dispersive X-ray (EDX) analysis was carried out to confirm the decomposition of CaCO 3 particles.
Drug Loading in
Capsule-Integrated Polypeptide Multilayer Films. Drug loading was conducted by incubating polypeptide multilayer films into 1 mg/mL FITC-BSA or RhoB-gentamicin solutions (pH 7.4, PBS buffered). The sample was washed in PBS for a few seconds to remove the loosely adsorbed drug molecules. To load FITC-BSA and RhoB-gentamicin in one film, polypeptide multilayer films of (PLL/PLGA) 3.5 /Capsule PLL /(PLL/PLGA) 10.5 /Capsule PLGA /(PLL/PL-GA) 10.5 were immersed in the FITC-BSA solution for 15 min followed by the RhoB-gentamicin solution. The loading of FITC-BSA and RhoBgentamicin in the capsules integrated within polypeptide multilayer films was confirmed using confocal laser scanning microscopy (CLSM, LSM 510, Zeiss, Thornwood, NY).
2.5. Drug Release from Capsule-Integrated Polypeptide Multilayer Films. A polypeptide multilayer film was incubated in a cuvette containing 2 mL of PBS (pH 7.4) in a water bath (37°C). At predetermined time periods, 0.4 mL of the PBS medium was taken for UV-vis measurements at 480 or 560 nm to quantify the release of FITC-BSA and RhoB-gentamicin, respectively. An equal volume of fresh PBS was added to keep a constant volume of release medium. All measurements were conducted in triplicate.
Results
Preparation of Multilayered Microparticles and
Capsules. CaCO 3 particles, approximately 7 µm in diameter, were used to prepare multilayered or shelled microparticles and capsules. The CaCO 3 particles had a nanoporous structure (Figure 2a inset) , and the pore size became smaller after impregnation of the polymers (e.g., PLGA; Figure 2b ). PLL or PLGA was successfully impregnated into the CaCO 3 particles. The amount of PLL or PLGA impregnated within CaCO 3 particles increased with increasing concentrations of PLL or PLGA solutions and reached saturation at about 2 mg/mL (Figure 3) . At the same concentration, more PLGA than PLL was impregnated into the particles. For instance, at 2 mg/mL, approximately 3.3 ng/particle of PLGA and 2.0 ng/particle of PLL were impregnated. After impregnation of PLGA or PLL inside CaCO 3 particles, PLL and PLGA were alternatively deposited to form a shell of (PLL/PLGA) 3.5 onto the particles (Figure 2c ). The CaCO 3 templates could be decomposed using EDTA, and the decomposition of CaCO 3 was confirmed using EDX, which showed the disappearance of the Ca peak ( Figure  2e ). PLGA or PLL impregnated capsules (i.e., Capsule PLGA or Capsule PLL ) were obtained (Figure 2d ). 60 min, at which the assembly of CaCO 3 particles almost reached a plateau (1.5-1.7 × 10 6 particles/cm 2 ). The assembly of shelled CaCO 3 particles in polypeptide multilayer films was examined using CLSM and SEM ( Figure  5 ). The fluorescence of RhoB-PLGA (Figure 5a1 and b1) had the same pattern as the CaCO 3 particles (Figure 5a2 ) and RhoB-PLGA was impregnated within CaCO 3 particles (Figure 5a1 ). Decomposition of CaCO 3 was subsequently achieved after treating with EDTA; the images under transmittance mode confirmed the decomposition of CaCO 3 particles (Figure 5a2  vs b2 ). The SEM image shows the morphology of the developed capsule-integrated polypeptide multilayer films (Figure 5c ). It seems that CaCO 3 particles tended to aggregate within polypeptide multilayer films, and a unique pattern of capsules within polypeptide multilayer films was observed (Figure 5c ). (Figure 7 ). Loading of two oppositely charged drug molecules within one polypeptide multilayer film was subsequently achieved. FITC-BSA was loaded into polypeptide multilayer films containing both Capsule PLL and Capsule PLGA (Figure 8a1 ,b1, top sections), while very little FITC-BSA was loaded into polypeptide multilayer films containing Capsule PLGA alone ( Figure  8a1,b1, bottom sections) . Moreover, both FITC-BSA and RhoBgentamicin were loaded into polypeptide multilayer films containing both Capsule PLGA and Capsule PLL (Figure 8a3 ,b2, top sections), while only RhoB-gentamicin was loaded into polypeptide multilayer films containing only Capsule PLGA (Figure 8a3 ,b2, bottom sections).
Assembly of
Drug Release from Capsule-Integrated Polypeptide Multilayer Films.
Release of FITC-BSA and RhoB-gentamicin from polypeptide multilayer films with and without capsules was performed. A burst release (within 1 day) followed by a sustained release of FITC-BSA and RhoB-gentamicin was obtained in polypeptide multilayer films of (PLL/PLGA) 3 respectively. By contrast, very little loading and release (∼5 µg/cm 2 ) of FITC-BSA was observed in (PLL/PLGA) 3.5 /Capsule PLGA /(PLL/PLGA) 10.5 films where both the drug BSA and the impregnated PLGA are negatively charged (Figure 9a) . Similarly, very little loading and release of FITC-BSA or RhoBgentamicin was found in polypeptide multilayer films without capsules (Figure 9a) .
Release of FITC-BSA and RhoB-gentamicin from one single polypeptide multilayer film was determined. Sustained release of both FITC-BSA and RhoB-gentamicin was obtained ( Figure  9b ) in polypeptide multilayer films of (PLL/PLGA) 3 
Discussion
We developed innovative capsule-integrated polypeptide multilayer films that allow for postpreparation loading of multiple drugs and simultaneous delivery of two oppositely charged drug molecules in a sustained and sequential manner. The introduction of drug binding sites within capsules was obtained by impregnating polyelectrolytes inside porous colloidal templates (i.e., CaCO 3 particles) followed by capsule formation. The amount of polyelectrolytes (e.g., PLGA) that could be impregnated inside capsules could be controlled by the concentration of polyelectrolytes (Figure 3) . LBL nanoassembly has been studied to prepare polypeptide multilayers on CaCO 3 particles [47] [48] [49] and here it was applied to deposit multilayers of (PLL/PLGA) 3.5 on CaCO 3 particles impregnated with polypeptides. The shelled CaCO 3 particles were treated with GA in excess, and the outermost layer (i.e., PLL) of the shelled CaCO 3 particles was therefore conjugated with GA through the reaction between aldehyde groups of GA and the amino groups of PLL. The surface of the CaCO 3 particles was consequently enabled with aldehyde groups 49 (see Supporting Information). These GA-treated CaCO 3 particles were deposited onto polypeptide multilayer films on quartz slides because their aldehyde groups react with the amino groups of the outermost layer (i.e., PLL) of polypeptide multilayer films 49 (see Supporting Information). The aldehyde groups also enabled the subsequent deposition of a PLL layer (Figure 1c) . As a result, shelled CaCO 3 particles were assembled within polypeptide multilayer films. The use of a cross-linking agent such as GA in this study was necessary. Without GA cross-linking, little adsorption of shelled CaCO 3 particles was observed in polypeptide multilayer films (see Supporting Information). Moreover, direct assembly of the capsules as a layer, based on electrostatic attraction, in the multilayer films led to substantially fewer capsules that could be adsorbed compared to the use of GA (data not shown). In addition, the use of shelled CaCO 3 particles instead of capsules is advantageous because the use of capsules will expose the impregnated polyelectrolytes to the subsequent LBL process. This will lead to potential interactions of the impregnated polyelectrolytes with oppositely charged polyelectrolytes, and therefore, the impregnated polyelectrolytes will not function as drug binding sites. Similarly, direct assembly of drug-carrying capsules in the multilayer films will lead to (i) the release of drugs during the subsequent LBL process of the films and (ii) interactions between the drug loaded and the subsequent LBL solutions. Therefore, the use of shelled particles, decomposed only in the final film preparation process, provides the multilayer films with the capability to load and release two or more oppositely charged drug molecules any time postpreparation. To our knowledge, such an approach has not been reported. In addition, by impregnating different polymers or other materials inside the porous particles, different types of drugs or other agents could be loaded and released.
Capsule-integrated polypeptide multilayer films were formed after decomposition of CaCO 3 templates using EDTA (Figures   1f and 5) . Loading of charged drug molecules into polyelectrolyte-impregnated capsules within polypeptide multilayer films was observed in situ ( Figures 6, 7, and 8) . FITC-gentamicin (green spots) was loaded in the capsules (red spots) and the loading was time-dependent ( Figure 6 ). Large macromolecules and even nanoparticles were reported to be loaded into polyelectrolyte multilayer films and microcapsules. 34, 35, 50, 51 Similarly, in this study, biomacromolecules like BSA were loaded into capsule-integrated polypeptide multilayer films, and relatively more loading of smaller drug molecules (i.e., gentamicin) was observed. The loading of drugs in capsule-integrated polypeptide multilayer films was mainly due to electrostatic interactions between the oppositely charged drugs and the polyelectrolytes impregnated inside the capsules. This is consistent with the observations that a significantly high amount (40 µg/cm 2 ) of negatively charged drug (i.e., FITC-BSA) was loaded into polypeptide multilayer films with PLL-impregnated capsules while very little (<5 µg/cm 2 or less than 10%) nonspecific loading of FITC-BSA was found in polypeptide multilayer films without capsules or with capsules impregnated with polyelectrolytes (i.e., PLGA) of the same charge as the Polypeptide Multilayer Film Biomacromolecules, Vol. 11, No. 12, 2010 3635 drug (Figures 8 and 9a) . The minimal loading of drugs inside the multilayer films or capsule walls was probably because most of the polymers in the multilayer films or capsule walls interact with their oppositely charged polymers during film buildup and had few net charges for interacting with the drug molecules. Moreover, sustained release of RhoB-gentamicin and FITC-BSA from capsule-integrated polypeptide multilayer films was achieved (Figure 9a,b) . Drug concentration difference between the polypeptide multilayer film and its environment was the main driving force that led to the release of drugs. Two oppositely charged drug molecules were successfully loaded into and released from one polypeptide multilayer film, that is, (PLL/ PLGA) 3.5 /Capsule PLL /(PLL/PLGA) 10.5 /Capsule PLGA /(PLL/PL-GA) 10.5 (Figures 8 and 9b) , and a sustained (up to two weeks or longer) drug release was observed (Figure 9b ). Compared to the release of gentamicin, the release of BSA was much slower, probably due to its larger molecular weight and its stronger hydrophobic interactions with PLL impregnated within the capsules. Gentamicin was completely released at day 14 while a substantial amount (i.e., 25%) of BSA still remained. This indicated that a sequential release of multiple drugs (e.g., release of two drugs within 14 days and one drug thereafter) was obtained in the developed capsule-integrated polypeptide multilayer films.
The concept of loading multiple therapeutic agents (especially agents with very different properties) within polyelectrolyte multilayer films after film preparation would be of real interest and has not been validated very well yet. It has been observed that certain combinations of polyelectrolytes allow for the completely irreversible loading of proteins 52 and nanoparticles could be reversibly loaded into exponentially growing polyelectrolyte multilayer films. 50 The significance of this study in finding a method to load multiple drugs postpreparation of film buildup include the following: (i) it would enable fast and universal preparation of the capsule-integrated films for a variety of applications, (ii) the polymer, intact postpreparation of film buildup, inside the capsules would enable flexible control over the types of drugs to be loaded, (iii) the use of polypeptides as film components would provide enormous potential for functionalization, and (iv) it would offer a universal approach to generate films with multiple functions on medical devices.
Conclusions
Advanced drug delivery systems were developed by integrating capsules within polypeptide multilayer films. Two oppositely charged model drugs were successfully loaded into capsuleintegrated polypeptide multilayer films by means of impregnating positively-or negatively charged polyelectrolytes as drugbinding agents within the capsules. The loading of charged drugs was mainly based on electrostatic interactions between the drugs and drug-binding agents within capsules. Polypeptide multilayer films were able to load multiple drugs postpreparation of films and to deliver two or more oppositely charged drugs at a sustained level (up to two weeks or longer) in a sequential manner. This provides an exciting new route to incorporate and deliver multiple drugs in a controlled manner, potentially at the implant/tissue interface, for medical applications (e.g., prevention of medical device-associated infections and stimulation of wound healing).
